Schröder, C P <br/><br/>
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.  [electronic resource] 

 -  The Journal of antimicrobial chemotherapy  May 1999 
 - 741-3 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0305-7453 
<br/><br/><label>Standard No.: </label>10.1093/jac/43.5.741  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Amphotericin B--economics<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Ciprofloxacin--economics<br/>Costs and Cost Analysis<br/>Cyclophosphamide--administration & dosage<br/>Drug Therapy, Combination<br/>Epirubicin--administration & dosage<br/>Female<br/>Fever--complications<br/>Fluorouracil--administration & dosage<br/>Granulocyte Colony-Stimulating Factor--economics<br/>Humans<br/>Length of Stay--economics<br/>Leukopenia--chemically induced<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Netherlands<br/>Prospective Studies<br/>Recombinant Proteins--economics